HCPLive Endocrinology

Endocrinology-focused updates for health care providers from @HCPLiveNews.

[HCPLive @HCPLiveNews]

#TLM24 may be over, but you can still keep up with the latest news, research, and expert perspectives from the meeting by following along with our coverage:
https://t.co/V9cpxhae0A

[HCPLive @HCPLiveNews]

BREAKING: The US Food and Drug Administration has issued a Complete Response Letter to Intercept Pharmaceuticals’ obeticholic acid (Ocaliva) for the treatment of #PBC, denying to approve the supplemental New Drug Application in its current form.

https://t.co/v9qGPLa4cV

[Patrick Campbell @RealPatCampbell]

“What we learned from FLOW is semaglutide saves kidneys, hearts, and lives”

Final on-site episode of #KidneyCompass from #KidneyWk.

Check out our earlier episodes using the link below 👇

https://t.co/8Q8j25HpmH

[HCPLive @HCPLiveNews]

What is the difference between Chat GPT-3.5 and GPT-4 in the diagnosis of skin disease among those in non-skin of color and skin of color patient groups?

Check out these new findings here:
https://t.co/FeuSrBnDv2

#dermatology

[Patrick Campbell @RealPatCampbell]

🚨 Breaking News!🚨

@EliLillyandCo's tirzepatide showed a 38% reduction in heart failure outcomes and improved symptoms in adults with HFpEF and obesity, according to topline data from the phase 3 SUMMIT trial.

Learn more:
https://t.co/830yjF2ZOd

#Obesity #HeartFailure

[HCPLive @HCPLiveNews]

🔒HCPLive exclusive: Adelina Hung, MD, of @ChicagoMedEdu @SinaiChicago, discusses innovations in #GERD and the FDA approval of vonoprazan (Voquezna) for non-erosive GERD.

👇 Check out a sneak peek below and sign up to access the full episode:
https://t.co/pVV3NzWF4X

[Patrick Campbell @RealPatCampbell]

Big weekend in Orlando at #ADASciSessions.

Quick 🧵 on top headlines through Sunday:
https://t.co/HzfdaJ92fv

#Diabetes #Obesity @ADA_DiabetesPro

[HCPLive Endocrinology @endocrinenetwrk]

Catch up on day one from ADA 2024!

[Patrick Campbell @RealPatCampbell]

Big first day at #ADASciSessions.

SURMOUNT-OSA - Is there anything incretin therapies can't do?
VX-880 Update
LENS trial finds fenofibrate offers benefit in DR
& More!

https://t.co/HzfdaJ9A53

#Diabetes #ADA2024 #ADA24 @AmDiabetesAssn @ADA_DiabetesPro

[Patrick Campbell @RealPatCampbell]

Last-minute packing for #ADA24 and then off to Orlando!

Super excited to see new data on tirzepatide, inhaled insulin, the CATALYST trial, and more this weekend!

Follow on @HCPLiveNews for the latest updates!

https://t.co/HzfdaJ92fv

[Patrick Campbell @RealPatCampbell]

New #DontMissABeat

Fresh off #ERA24, @BrendonNeuen joins @MVaduganathan & @SJGreene_MD to discuss semaglutide, FLOW, and the future of cardiorenal protection.
https://t.co/AVmxQj2H4s

#Nephrology #Cardiology

[HCPLive @HCPLiveNews]

"We used a claims database to evaluate the risk of postoperative respiratory complications among patients with #diabetes and a prescription fill for GLP-1 RAs."

https://t.co/5VrqtcprVf

[Patrick Campbell @RealPatCampbell]

In the latest #DiabetesDialogue, @AlanLotvinMD joins @DianaMIsaacs and @natalie_bellini to discuss what the #diabetes community needs to know about the latest FDA-cleared automated insulin delivery system: Sequel Med Tech's twiist.

Full episode:
https://t.co/c3Qdvuwi8B

[HCPLive @HCPLiveNews]

Part 2 of the Question List:

[HCPLive @HCPLiveNews]

🚨 We are just days away from our #PreACCChat with @APAC_Cardiology on April 1 from 8-9 PM ET ! 🚨

Check out our 10 questions and posting times to prepare for the evening and participate on Monday night!

#CardioTwitter #Cardiology #ACC24

Part 1:

[HCPLive @HCPLiveNews]

Get a recap of top news and data related to automated insulin delivery from #ATTD2024 in the latest episode of #DiabetesDialogue!

https://t.co/YjqtzzzXLC

[Patrick Campbell @RealPatCampbell]

ACC.24 Tweet Chat on Monday from 8-9 PM from @HCPLiveNews and @APAC_Cardiology!!

Questions list posted tomorrow on:
https://t.co/PYanK1wmK5

#Cardiology #Cardiotwitter #ACC24

[HCPLive @HCPLiveNews]

🚨 We are 10 days away from our pre-ACC Tweet Chat with @APAC_Cardiology! 🚨

Join us on April 1 at 8 PM ET for a 10-question tweet chat discussing all things #ACC24, including the most anticipated sessions, pressing research needs, and more!
https://t.co/YrnGBuMwgw
#Cardiology

[Patrick Campbell @RealPatCampbell]

In this episode of #DiabetesDialogue, @brendonneuen joins @DianaMIsaacs & @natalie_bellini talk about the FLOW trial, the concept of 4 pillars of GDMT for CKD in T2D, and how to approach sequencing of new therapies.
https://t.co/RvBALFJiuI
#ChronicKidneyDisease #Diabetes

[Patrick Campbell @RealPatCampbell]

"The future is so bright. We're in a unique period in medicine"

SURMOUNT-2 lead Dr. Garvey on the future of incretin therapies, including tirzepatide, retatrutide, survodutide & CagriSema, in the latest #DiabetesDialogue.
https://t.co/SjE6BkgF0n

@DianaMisaacs @natalie_bellini

[Patrick Campbell @RealPatCampbell]

How does SELECT change management of CV risk?
In the latest #DiabetesDialogue special guest @LincoffMichael joins @DianaMIsaacs and @natalie_bellini to discuss SELECT, its implications, and the future of incretin therapies.

https://t.co/eeak9V9v2C

#Obesity #Diabetes #Cardiology